• Vemurafenib Workflows for Melanoma Resistance

  2026-08-31

  Vemurafenib (PLX4032) provides a controlled way to interrogate BRAF V600E signaling, melanoma cell proliferation inhibition, and adaptive drug resistance. This research workflow connects dose-response assays with phospho-signaling and multi-omics designs, helping distinguish true pathway dependence from paradoxical RAF activation.

• Phosbind Acrylamide: Workflow and Troubleshooting

  2026-08-30

  Phosbind Acrylamide enables phosphate-dependent mobility shifts in SDS-PAGE, offering an antibody-sparing route to compare phosphorylated and non-phosphorylated proteins. This practical workflow connects the reagent to SepM–ComDE signaling research while emphasizing controls, gel preparation, and troubleshooting limits.

• DiscoveryProbe Natural Product Library Plus Workflow

  2026-08-29

  Turn a diverse natural product library into a disciplined path from primary enzyme inhibition to cell-based validation. This workflow uses the DiscoveryProbe™ Natural Product Library Plus to support reproducible HTS, orthogonal confirmation, and mechanism-aware hit triage for challenging targets such as Cryptosporidium parvum AdhE.

• Bifendate (DDB): Liver Assay Workflows

  2026-08-28

  Bifendate (DDB) combines hepatoprotection research with mechanistic control of lysosomal autophagy and lipid-droplet accumulation. This practical guide translates the reference study into cell-based workflows, animal-study planning, assay controls, and troubleshooting strategies.

• ERK5, Vitamin D, and Myeloid Leukemia Differentiation

  2026-08-28

  The reference study separates the roles of ERK5 and ERK1/2 in 1α,25-(OH)2 vitamin D3-induced differentiation of AML cell lines. Its key contribution is showing that ERK5 inhibition changes differentiation-marker patterns while also producing cell-cycle arrest, particularly in G2, providing a mechanistic basis for combining vitamin D derivatives with ERK5-directed strategies.

• SB 431542 for TGF-β EndMT Studies

  2026-08-27

  Use SB 431542 as a selective ALK5 inhibitor to test whether TGF-β receptor activity drives PM2.5-induced endothelial–mesenchymal transition. This workflow combines Smad phosphorylation, endothelial and mesenchymal markers, lncRNA analysis, migration, and proliferation readouts for stronger mechanistic conclusions.

• Estramustine Compliance in Very High-Risk Prostate Cancer

  2026-08-27

  This prospective study found that reduced estramustine phosphate exposure during six-month neoadjuvant chemohormonal therapy with degarelix acetate was associated with inferior biochemical recurrence-free survival in very high-risk prostate cancer. Its main contribution is to identify treatment compliance, alongside disease-risk category, as a clinically informative factor while highlighting substantial toxicity and the limits of causal interpretation.

• Fingolimod (FTY720) and Immune Trafficking

  2026-08-26

  Fingolimod (FTY720) offers translational researchers a controllable way to study S1P-regulated lymphocyte trafficking, CNS signaling, and the design constraints of emerging in vivo CAR-T-mimicking platforms.

• Y-27632 Dihydrochloride: ROCK Inhibitor Workflows

  2026-08-26

  Y-27632 dihydrochloride provides a selective way to interrogate ROCK1/2-dependent cytoskeletal tension, survival, and invasion phenotypes. This practical guide connects dose-finding, stem-cell handling, 3D models, and translational assay design while distinguishing established product data from workflow recommendations.

• Maraviroc (UK-427857) Experimental Workflows

  2026-08-25

  Maraviroc enables controlled CCR5 perturbation across HIV-1 entry inhibition, HIV tropism studies, and exploratory neuroinflammation modulation. This practical guide connects nanomolar pharmacology with time-resolved ischemic-stroke assays, emphasizing solvent control, matched vehicle experiments, and interpretation limits.

• DAF-2 diacetate for Soybean Nodule NO Imaging

  2026-08-25

  DAF-2 diacetate converts sulfur-dependent reactive nitrogen species biology into a spatial, live-cell fluorescence readout for soybean nodule research. This workflow guide covers probe handling, reference-aligned experimental design, controls, imaging optimization, and limits for broader nitric oxide studies.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-08-24

  Masitinib (AB1010) provides a DMSO-compatible approach for selective KIT, PDGFRα, and PDGFRβ inhibition in cancer biology, mast cell, and inflammatory research. It is not appropriate for aqueous or ethanol-based protocols, and its dossier-level activity should not be treated as evidence for broad kinase inhibition or a clinical treatment recommendation.

• SB 202190: p38 MAP Kinase Inhibitor Workflow

  2026-08-24

  Build cleaner inflammation, cancer, and neurobiology experiments with SB 202190, a selective p38α/β inhibitor suited to pathway-causality studies. This workflow connects astrocyte–microglia crosstalk, apoptosis assay design, compound handling, and translational model selection.

• FRQ Phosphorylation Clusters Set Circadian Period

  2026-08-23

  Wang, Stevenson, and Dunlap systematically tested all 110 reported phosphorylation sites on the Neurospora FRQ clock protein, revealing regional clusters that differentially control circadian period and temperature compensation. Their mutational and luciferase-based strategy shows that FRQ phosphorylation is distributed across functionally distinct regions and can display intramolecular epistasis, providing a framework for multisite protein phosphorylation analysis.

• Par6 Drives Processive Lgl Phosphorylation by aPKC

  2026-08-22

  The reference study combines cryo-EM with protein biochemistry to explain how Par6b converts aPKCι-mediated Lgl2 phosphorylation from a distributive reaction into a processive one. Its findings identify a dynamic, multi-surface complex that keeps Lgl2 engaged with the kinase long enough to acquire multiple phosphates, clarifying how epithelial polarity is established.

8622 records 1/575 page Next 12345 下5页 Last page